Phase I Trial of NGR-TNF Administered Every 3 Weeks as a 1 Hour Intravenous Infusion in Patients With Solid Tumor.
Phase of Trial: Phase I
Latest Information Update: 09 Sep 2016
At a glance
- Drugs Tumour necrosis factor alpha (Primary)
- Indications Colon cancer; Head and neck cancer; Renal cancer; Solid tumours; Thyroid cancer
- Focus Adverse reactions
- 27 Nov 2007 Status change from recruiting to in progress.
- 24 Aug 2005 New trial record.